Literature DB >> 33551818

Integrating Network Pharmacology and Experimental Validation to Investigate the Effects and Mechanism of Astragalus Flavonoids Against Hepatic Fibrosis.

Lin An1, Yuefang Lin1, Leyan Li1, Muyan Kong1, Yanmei Lou1, Jinjun Wu1, Zhongqiu Liu1.   

Abstract

Hepatic fibrosis (HF) represents the excessive wound healing where an excess amount of connective tissues is formed within the liver, finally resulting in cirrhosis or even hepatocellular carcinoma (HCC). Therefore, it is significant to discover the efficient agents and components to treat HF, thus restraining the further progression of hepatopathy. Astragalus membranaceus (Fisch.) Bunge [also called Astragali Radix (AR)] is a famous herb in traditional Chinese medicine (TCM), which possesses a variety of biological activities and exerts good therapeutic effects in the treatment of HF. Flavonoids account for the major active ingredients related to the AR pharmacological effects. Total AR flavonoids have been proved to exert inhibitory effects on hepatic fibrosis. This study aimed to further undertake network pharmacology analysis coupled with experimental validation and molecular docking to investigate the effects and mechanism of multiple flavonoid components from AR against liver fibrosis. The results of the network pharmacology analysis showed that the flavonoids from AR exerted their pharmacological effects against liver fibrosis by modulating multiple targets and pathways. The experimental validation data showed that the flavonoids from AR were able to suppress transforming growth factor beta 1 (TGF-β1)-mediated activation of hepatic stellate cells (HSCs) and reduce extracellular matrix deposition in HSC-T6 cells via regulating the nuclear factor kappa B (NF-κB) signal transduction pathway. The results of the molecular docking study further showed that the flavonoids had a strong binding affinity for IκB kinase (IKKβ) after docking into the crystal structure. The above results indicated that, flavonoids possibly exerted the anti-inflammatory effect on treating HF by mediating inflammatory signaling pathways. The potential mechanism of these flavonoids against liver fibrosis may be related to suppression of the NF-κB pathway through effective inhibition of IKKβ. This study not only provides a scientific basis for clarifying the effects and mechanism of AR flavonoids against liver fibrosis but also suggests a novel promising therapeutic strategy for the treatment of liver fibrosis.
Copyright © 2021 An, Lin, Li, Kong, Lou, Wu and Liu.

Entities:  

Keywords:  Astragalus membranaceus (fisch) bunge; anti-inflammation; flavonoids; liver fibrosis; network pharmacology

Year:  2021        PMID: 33551818      PMCID: PMC7862122          DOI: 10.3389/fphar.2020.618262

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  50 in total

Review 1.  Network analyses in systems pharmacology.

Authors:  Seth I Berger; Ravi Iyengar
Journal:  Bioinformatics       Date:  2009-07-30       Impact factor: 6.937

2.  Preparation of Astragalus membranaceus lectin and evaluation of its biological function.

Authors:  Chong-Zhi Bai; Jian-Qing Hao; Xu-Liang Hao; Ma-Li Feng
Journal:  Biomed Rep       Date:  2018-07-18

Review 3.  Network pharmacology: a Rosetta Stone for traditional Chinese medicine.

Authors:  Da Cheng Hao; Pei Gen Xiao
Journal:  Drug Dev Res       Date:  2014-08       Impact factor: 4.360

4.  Effect of Astragalus complanatus flavonoid on anti-liver fibrosis in rats.

Authors:  Chun-Yu Liu; Zhen-Lun Gu; Wen-Xuan Zhou; Ci-Yi Guo
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

5.  Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers.

Authors:  T Takahara; K Furui; Y Yata; B Jin; L P Zhang; S Nambu; H Sato; M Seiki; A Watanabe
Journal:  Hepatology       Date:  1997-12       Impact factor: 17.425

6.  Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency.

Authors:  Enrica Ek Tan; Richard A Hopkins; Chrissie K Lim; Saumya S Jamuar; Christina Ong; Koh C Thoon; Mark Ja Koh; Eun Mong Shin; Derrick Wq Lian; Madhushanee Weerasooriya; Christopher Zw Lee; Andreas Alvin Pumomo Soetedjo; Chang Siang Lim; Veonice B Au; Edmond Chua; Hui Yin Lee; Leigh Ann Jones; Sharmy S James; Nivashini Kaliaperumal; Jeffery Kwok; Ee Shien Tan; Biju Thomas; Lynn Xue Wu; Lena Ho; Anna Marie Fairhurst; Florent Ginhoux; Adrian Kk Teo; Yong Liang Zhang; Kok Huar Ong; Weimiao Yu; Byrappa Venkatesh; Vinay Tergaonkar; Bruno Reversade; Keh Chuang Chin; Ah Moy Tan; Woei Kang Liew; John E Connolly
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site.

Authors:  Roger Kist; Luis Fernando Saraiva Macedo Timmers; Rafael Andrade Caceres
Journal:  J Mol Graph Model       Date:  2017-12-24       Impact factor: 2.518

8.  Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease.

Authors:  Jiansheng Li; Peng Zhao; Ya Li; Yange Tian; Yonghua Wang
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

9.  Network Pharmacology Identifies the Mechanisms of Action of Shaoyao Gancao Decoction in the Treatment of Osteoarthritis.

Authors:  Naiqiang Zhu; Jingyi Hou; Guiyun Ma; Jinxin Liu
Journal:  Med Sci Monit       Date:  2019-08-14

10.  A novel chemometric method for the prediction of human oral bioavailability.

Authors:  Xue Xu; Wuxia Zhang; Chao Huang; Yan Li; Hua Yu; Yonghua Wang; Jinyou Duan; Yang Ling
Journal:  Int J Mol Sci       Date:  2012-06-07       Impact factor: 6.208

View more
  11 in total

1.  [Therapeutic mechanism of the Mongolian medicine Qiwei Qinggan Powder against liver fibrosis based on UHPLC-TOF-MS combined with network pharmacological methods].

Authors:  C Zhang; Y Yan; X Gao; Y Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-08-20

2.  Grevillea robusta Delayed the Progression of Experimentally Induced Hepatic Fibrosis and Cirrhosis in Wistar Rats by Attenuating the Expression of Smooth Muscle Actin, Collagen, and TGF-β.

Authors:  Saaid Hameed; Atta Ur Rehman; Shazma Massey; Nawazish-I-Husain Syed; Fareeha Anwar; Dildar Ahmed; Sarfraz Ahmad
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

3.  Exploration on Molecular Mechanism of Reversal Effect of Compound Danshen Tablets on Hepatic Fibrosis Based on Network Pharmacology.

Authors:  Minling Cao; Jingyue Fan; Xiaoli Yang; Meifeng Shi; Shanshan Lin; Xiaolin Chi
Journal:  Appl Bionics Biomech       Date:  2022-05-10       Impact factor: 1.664

4.  Dissecting and Evaluating the Therapeutic Targets of Coptis Chinensis Franch in the Treatment of Urinary Tract Infections Induced by Escherichia coli.

Authors:  Zhenglin Chang; Jinhu Zhang; Min Lei; Zheng Jiang; Xiangkun Wu; Yapeng Huang; Zhican He; Yuyan Zhang; Shujue Li; Xiaolu Duan; Wenqi Wu
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.810

5.  Network Pharmacology and Experimental Validation to Reveal the Pharmacological Mechanisms of Liuwei Dihuang Decoction Against Intervertebral Disc Degeneration.

Authors:  Huihao Zhang; Sai Yao; Zhiguo Zhang; Chengcong Zhou; Fangda Fu; Yishan Bian; Huan Luo; Yan Li; Shuxin Yan; Yuying Ge; Yuying Chen; Kunyu Zhan; Yanzhi Ge; Zuxiang Chen; Ming Yue; Xiaofeng Li; Weibin Du; Hongting Jin; Peijian Tong; Hongfeng Ruan; Chengliang Wu
Journal:  Drug Des Devel Ther       Date:  2021-12-02       Impact factor: 4.162

6.  Integration of Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanisms of Zhuanggu Busui Formula Against Osteoporosis.

Authors:  Huihao Zhang; Chengcong Zhou; Zhiguo Zhang; Sai Yao; Yishan Bian; Fangda Fu; Huan Luo; Yan Li; Shuxin Yan; Yuying Ge; Yuying Chen; Kunyu Zhan; Ming Yue; Weibin Du; Kun Tian; Hongting Jin; Xiaofeng Li; Peijian Tong; Hongfeng Ruan; Chengliang Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-28       Impact factor: 5.555

7.  Role of NOD-Like Receptors in a Miniature Pig Model of Diabetic Renal Injuries.

Authors:  Yi Ren; Shaoyuan Cui; Quan Hong; Wanjun Shen; Qinggang Li; Lingling Wu; Bo Fu; Xu Wang; Qian Ma; Jiaona Liu; Xueyuan Bai; Xiangmei Chen
Journal:  Mediators Inflamm       Date:  2022-03-30       Impact factor: 4.711

8.  The effect and mechanism of cypermethrin-induced hippocampal neurotoxicity as determined by network pharmacology analysis and experimental validation.

Authors:  Jianan Li; Haoran Bi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 9.  Astragalus Mongholicus: A review of its anti-fibrosis properties.

Authors:  Fengying Gong; Rongmei Qu; Yongchun Li; Ying Lv; Jingxing Dai
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

10.  Exploring the Protective Effects and Mechanism of Crocetin From Saffron Against NAFLD by Network Pharmacology and Experimental Validation.

Authors:  Zijin Xu; Susu Lin; Junjie Gong; Peishi Feng; Yifeng Cao; Qiaoqiao Li; Yuli Jiang; Ya You; Yingpeng Tong; Ping Wang
Journal:  Front Med (Lausanne)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.